Where I see patients (2)
我的评论
Selected research
-
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, 一期试验.
《十大赌博平台排行榜》. 肿瘤学
-
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma 病人 Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Clinical genitourinary cancer
-
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Frontiers in oncology
联系我
- Request appointment
- Refer a patient
- (415) 476-4616
4.9